Maple Syrup Urine Disease: Clinical Management and Genetic Insights

Maple Syrup Urine Disease (MSUD) is an autosomal recessive metabolic disorder resulting from deficient activity of the branched-chain α-ketoacid dehydrogenase complex (BCKDH), impairing catabolism of leucine, isoleucine and valine. The ensuing accumulation of branched-chain amino acids (BCAAs) and their corresponding ketoacids leads to neurotoxicity, developmental delay and, if untreated, potentially fatal cerebral oedema. Clinical management hinges upon early diagnosis through newborn screening, strict dietary restriction of BCAAs, supplementation of thiamine in responsive phenotypes, and in severe or unresponsive cases, liver transplantation to restore peripheral BCKDH activity. Recent advances in genetic sequencing have expanded the spectrum of pathogenic variants across BCKDHA, BCKDHB and DBT genes, highlighting genotype–phenotype correlations that inform prognostic assessment and family counselling. Emerging metabolomic profiling techniques promise novel biomarkers for early detection, while inherited and environmental modifiers are under investigation to refine therapeutic strategies. Despite improvements in survival, long-term neurological outcomes remain variable, underscoring the need for integrated approaches that combine molecular diagnostics, targeted therapies and interdisciplinary care.

Research from Nature Portfolio

Recent studies have expanded the genotypic and phenotypic spectrum of MSUD by identifying novel pathogenic variants in diverse populations. In a cohort of Egyptian children, comprehensive sequencing of BCKDHA, BCKDHB and DBT genes revealed previously unreported mutations and copy-number variants, demonstrating that early aggressive dietary management can yield normal developmental outcomes even in resource-limited settings. Another foundational investigation explored repurposing of a widely used anti-diabetic drug to address metabolic derangements in a murine intermediate MSUD model. Treatment with metformin significantly reduced skeletal muscle and serum levels of branched-chain ketoacids, restored mitochondrial metabolite balance and improved muscle function, suggesting a potential adjunctive therapy to dietary restriction and transplantation. These findings highlight the translational potential of genotype-tailored interventions and small molecule approaches in MSUD.

Maple Syrup Urine Disease: Clinical Management and Genetic Insights publication trend

The graph below shows the total number of articles in maple syrup urine disease: clinical management and genetic insights across all publications each year (not limited to Nature Index journals).

Technical terms

Branched-chain amino acids (BCAAs): Essential amino acids leucine, isoleucine and valine that require catabolism by the BCKDH complex.

Branched-chain α-ketoacid dehydrogenase (BCKDH) complex: A mitochondrial multienzyme complex responsible for irreversible decarboxylation of branched-chain α-ketoacids derived from BCAAs.

Untargeted metabolomics: A high-throughput analytical approach profiling a wide range of metabolites without predefined targets to discover novel biomarkers and pathways.

Newborn screening (NBS): A public health programme employing biochemical assays on blood spots to detect treatable inherited metabolic disorders early in life.

L-alloisoleucine: A non-proteinogenic diastereomer of isoleucine that accumulates specifically in MSUD and serves as a diagnostic biomarker.

References

1. Exploratory Untargeted Metabolomics of Dried Blood Spot Samples from Newborns with Maple Syrup Urine Disease. International Journal of Molecular Sciences (2024).
2. Expanding the genotypic and phenotypic spectrum of Egyptian children with maple syrup urine disease. Scientific Reports (2024).
3. Comprehensive Iranian guidelines for the diagnosis and management of maple syrup urine disease: an evidence- and consensus- based approach. Orphanet Journal of Rare Diseases (2025).
4. Metformin inhibits Branched Chain Amino Acid (BCAA) derived ketoacidosis and promotes metabolic homeostasis in MSUD. Scientific Reports (2016).
5. Challenges in Diagnosing Intermediate Maple Syrup Urine Disease by Newborn Screening and Functional Validation of Genomic Results Imperative for Reproductive Family Planning. International Journal of Neonatal Screening (2021).